Allergan Licenses Molecular Partners’ Mid-Stage Ophthalmology Drug in US$420 M Deal
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 5 (Table of Contents)
Published: 10 May-2011
DOI: 10.3833/pdr.v2011.i5.1470 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Allergan has agreed to pay up to US$420 M, plus tiered, double-digit royaties, to gain exclusive global rights to Molecular Partners’ retinal disease drug candidate MP0112 for ophthalmic indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS